LFVN earnings analysis
What we found in LFVN's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
LifeVantage's fiscal 2026 results show a material deterioration in demand: revenue declined 20.1% to $182.586 million, operating margin fell to 3.4% from 5.4%, and active accounts declined 21.2% to 104,000. The LoveBiome acquisition and P84 launch provide a potentially meaningful product roadmap, with P84 contributing $9.1 million of revenue, but this was insufficient to offset the $18.3 million decline in MindBody GLP-1 revenue and declines in Protandim and TrueScience. Operating cash flow remained positive at $10.241 million and the company continued dividends and buybacks, but shrinking customers, lower margins, tariff exposure, and new AI compliance risks weigh on the outlook.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- P84 adds a new growth platform
- LifeVantage launched the P84 System and other LoveBiome-derived products during fiscal 2026. The P84 System generated $9.1 million of revenue for the year, including $6.3 million from LoveBiome consultants after the acquisition date.
- Broad product and geographic roadmap
- The company expanded its product roadmap across gut health, weight management, energy, hydration, pets, and skincare, including the P84 System, AXIO X, AXIO Hydrate, Petandim in Mexico, and market launches in Iceland and Portugal. The P84 System's in vitro study showed activation of 14 key gut peptides.
- Business remained profitable
- Despite the revenue decline, fiscal 2026 remained profitable: net income was $5.072 million and diluted EPS was $0.40. The effective tax rate declined to 16.4% from 19.9% in fiscal 2025.
- Positive operating cash generation
- The company generated $10.241 million of operating cash flow and ended the year with $14.920 million of cash. It also reduced inventory from $20.669 million to $16.167 million, aided by inventory management actions.
- Continued shareholder returns
- Capital returns continued through a $2.344 million dividend and $2.043 million of share repurchases in fiscal 2026. The board authorized repurchases of up to $60.0 million through December 31, 2027, with $58.5 million remaining at year-end.
- Digital infrastructure investment
- LifeVantage is investing in a modern e-commerce platform, consultant tools, data integration, and future artificial-intelligence capabilities. Fiscal 2026 capital expenditures were $3.571 million, primarily related to the new e-commerce platform.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Customer and consultant base contracted
- Revenue fell to $182.586 million from $228.530 million, while operating income declined to $6.100 million from $12.199 million and gross margin fell to 77.6% from 80.4%. Active accounts dropped 21.2% to 104,000, including a 24.7% decline in active customers to 61,000.
- New AI compliance and governance exposure
- The filing introduces extensive AI-related risks as the company and consultants use AI for marketing, product development, forecasting, and compliance. AI-generated consultant content could contain non-compliant health or income claims, potentially triggering investigations, fines, penalties, litigation, or reputational harm; the company also notes that it has limited visibility into consultant AI use.
- Tariffs and foreign exchange pressure margins
- The filing identifies materially changed tariff exposure: after a 10% global tariff effective February 24, 2026 expired on July 24, 2026, new tariffs of 10% and 12.5% were announced on goods from 60 U.S. trade partners. Purchases from suppliers are generally in U.S. dollars while sales are generally in local currencies, increasing sensitivity to tariffs and currency movements.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.4
- Gross margin
- 77.6%
- Operating margin
- 3.4%
- Segment
- Single reporting segment: integrated direct sales through independent consultants
- Segment
- Americas: $142.716 million, 78.2% of revenue; down 23.2% year over year
- Segment
- Asia/Pacific & Europe: $39.870 million, 21.8% of revenue; down 6.9% year over year
- Segment
- United States: $135.404 million, approximately 74% of total revenue; down 24.1% year over year
- Segment
- Japan: $24.148 million, approximately 13% of total revenue; down 4.9% year over year
- Segment
- Product lines: Protandim $81.989 million, TrueScience $37.853 million, LifeVantage $32.258 million, AXIO $15.006 million, LoveBiome $9.121 million, Petandim $1.961 million, and Other $4.398 million
What they said about what is next.
The 10-K provides no quantitative revenue or EPS outlook. Management states that cash and ongoing operating cash flow should satisfy requirements for at least the next 12 months, while noting that future growth depends on new products, consultant/customer retention, and international expansion.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 6, 2026
- LifeVantage Corporation's Q3 2026 results reflect a significant decline in revenue and earnings, continuing from prior quarters. Revenue decreased to $43.7 million, down from $58.4 million in Q3 2025, resulting in an…
- 10-K · September 4, 2025
- LifeVantage frames its strategy around nutrigenomics and a direct‑selling model, emphasizing product innovation (notably the patent‑pending MindBody GLP‑1 System™ launched in fiscal 2025), technology‑enabled consultant…
- 10-K · August 28, 2024
- LifeVantage positions itself as a nutrigenomics-focused direct‑selling company emphasizing product ‘activation’ (Protandim®, TrueScience®, AXIO®, etc.), technology-enabled consultant tools, and expanded compensation and…
- 10-Q · May 2, 2024
- LifeVantage reported quarter revenue of $48,245,000, down from $53,741,000 a year earlier, while gross margin remained high at 78.9% and operating income improved to $1,934,000. Net income and diluted EPS rose to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LFVN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever